Abstract :
Background: For endometrial carcinoma, the main surgical treatment is total hysterectomy and bilateral salpingo -oophorectomy. Women with high-risk endometrial cancer have a relatively higher recurrence rates and poor prognosis following hysterectomy alone. Therefore, pelvic external beam radiotherapy has bee n the standard adjuvant treatment for these patients. This is a prospective study on patients with high-risk endometrial cancer evaluating the benefit of adding concurrent weekly paclitaxel with adjuvant radiotherapy, versus radiotherapy alone.
Methods: Eligible patients were randomized to Arm A; Concurrent chemotherapy with radiotherapy [CCRT], and Arm B; External beam pelvic radiotherapy alone [RTH]. Pelvic radiotherapy was 50.4Gy over 28 fractions, and chemotherapy course was weekly paclitaxel (50mg/m2) for 5 weeks. Patients were evaluated for treatment related toxicities, disease failures and survival.
Conclusion: Adding concurrent paclitaxel to pelvic radiotherapy in high-risk endometrial cancer patient is safe and tolerable, and tends to decrease treatment failures, even though this not translated to OS nor DFS improvement.
Keyword: Endometrial Carcinoma; Radiotherapy; Concurrent Chemotherapy